Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 16, 2023 16:30 ET
|
Gritstone bio
EMERYVILLE, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone bio and Genevant Sciences Announce Option and License Agreement
August 15, 2023 07:00 ET
|
Gritstone bio
Agreement provides nonexclusive access to Genevant’s leading LNP technology for use with Gritstone bio’s self-amplifying RNA technology in wide array of infectious disease vaccines Multi-year,...
Gritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
August 09, 2023 16:05 ET
|
Gritstone bio
-- Enrollment completed in Phase 2 portion of Phase 2/3 study evaluating GRANITE (personalized cancer vaccine [PCV]) in first-line metastatic microsatellite-stable colorectal cancer (MSS-CRC);...
Gritstone bio Partners with Friends of Cancer Research (Friends) on the ctDNA to Monitor Treatment Response (ctMoniTR) Project
August 07, 2023 07:00 ET
|
Gritstone bio
EMERYVILLE, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 17, 2023 07:00 ET
|
Gritstone bio
EMERYVILLE, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 13, 2023 07:00 ET
|
Gritstone bio
EMERYVILLE, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone bio Announces Publication of Interim Results from Phase 1 Study of Self-amplifying mRNA (samRNA) Vaccine Against COVID-19 in Nature Communications
June 08, 2023 07:00 ET
|
Gritstone bio
-- Potent and durable immunogenicity achieved with low dose self-amplifying mRNA vaccine (samRNA) candidate -- -- Immunity boosted for at least 6 months in previously vaccinated-older adults...
Gritstone bio to Participate in Upcoming Investor Conferences
June 01, 2023 16:30 ET
|
Gritstone bio
EMERYVILLE, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 24, 2023 17:00 ET
|
Gritstone bio
EMERYVILLE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced...
Gritstone bio Reports First Quarter 2023 Financial Results and Provides Corporate Updates
May 11, 2023 16:05 ET
|
Gritstone bio
-- Robust enrollment in Phase 2 portion of randomized Phase 2/3 study of GRANITE (personalized vaccine in first-line metastatic microsatellite-stable colorectal cancer [MSS-CRC]) to date; 71 of 80...